A Phase 2 interventional study of The high-dose group of ZL-82 tablets and The low-dose group of ZL-82 tablets in Atopic Dermatitis, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.
Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 125th largest by planned enrollment of the 190 interventional ones that give a count, is one of 32 that started in 2026, is one of 58 in phase 2, reaches primary completion later than 59 of the 81 other live ones, and was the 144th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Sites in China
Ages 18–75
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 2–11
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
QuantX Biosciences, Inc. · Sites in China
Ages 18 mo–65 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 53 · Phase 2 76 · Phase 3 63 · Phase 4 5
First in 2011; this study’s year is marked. 32 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 111 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 164 across the 190 interventional studies, 472 across the 16 observational. Of the 114 that completed or were terminated, 22 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 206 have an industry lead sponsor. The 10 most frequent:
Chengdu Zenitar Biomedical Technology Co., Ltd is the lead sponsor of 23 studies on the registry; 12 are open to participants now.
Chengdu Zenitar Biomedical Technology Co., Ltd has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
27 of the studies in Dermatitis, Atopic with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775860Phase 3Beijing InnoCare Pharma Tech Co., Ltd.ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | 2026-11-25 |
| NCT07540442Phase 3Shanghai Mabgeek Biotech.Co.LtdA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-01-05 |
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
| NCT06880276Phase 3Qilu Pharmaceutical Co., Ltd.Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | 2027-03 |
| NCT07386743Phase 3Jiangsu Genscend Biopharmaceutical Co., LtdA Phase III Study of GS101 Injection to Dupixent® | 2027-04 |
Add all 27 to your calendar (.ics) → With an account.
Among the 206 studies in Dermatitis, Atopic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to explore whether the drug ZL-82 tablets can be used to treat moderate to severe atopic dermatitis in adults, and to understand the safety and tolerability of the drug. The main questions that the trial intends to answer are: Can ZL-82 tablets alleviate the Eczema Area and Severity Index (EASI) score of patients? What physical problems will patients have after taking ZL-82 tablets? The researchers will compare ZL-82 tablets with placebo (a substance with a similar appearance but without drug components) to observe whether ZL-82 tablets can be used to treat moderate to severe atopic dermatitis. Participants need to take ZL-82 tablets or placebo every day for 16 weeks, and visit the hospital for a check-up every two weeks; record their own symptoms and the percentage change of EASI score relative to the baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4 . The definition of moderate to severe atopic dermatitis during screening and baseline period is as follows:
BSA (body surface area) affected by AD >= 10% (BSA: body surface area, in this trial, BSA is based on the average human body surface area of 1.6 m2); 5. Participants who have been treated with local drugs, calcineurin inhibitors, or phototherapy within the past 6 months, and whose medical history indicates inadequate response, no response, or intolerance to these treatments, or who have medical for such treatments (treatment duration ≥ 4 weeks), and who require systemic treatment to control the disease, should be selected. Note: For stable treatment response that is insufficient when using local drugs (such as moderate-to-high potency topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)), insufficient response is defined as participants receiving treatment for the recommended duration or the maximum recommended duration as per the instructions, but failing to achieve and maintain disease remission (corresponding to IGA score = 0 [clear] - 2 [mild]).
6. Use a mild moisturizing agent (moisturizing cream) at a stable dose twice a day for at least 7 consecutive days before the first day of administration, and agree to continue using it during the study.
Exclusion Criteria:
Use of any of the following drugs or treatments:
a. Within 1 month before the baseline, received other oral JAK inhibitor treatment, or had a lack of efficacy or intolerance to other oral JAK inhibitors, including but not limited to baricitinib, upadacitinib, abrocitinib, etc.; b. Within 6 weeks before the baseline, used upadilunab/spicibaydin; c. Within 3 months before the baseline (or within 5 drug half-lives, whichever is longer), used other systemic biological agents known or potentially affecting AD other than dupilumab (such as IL-13 receptor antibody [crizorilumab], IL-31Rα antibody [nimotuzumab] etc.); d. Within 1 week before the baseline, used any AD topical treatment: TCS, TCI, PDE-4 inhibitor, JAK inhibitor, traditional Chinese medicine / Chinese patent medicine, herbal medicine, etc.; e. Within 4 weeks before the baseline (or within 5 half-lives, whichever is longer), used any systemic treatment for AD: (such as cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, etc.), , PDE-4 inhibitor, etc.; f. Within 4 weeks before the baseline received any systemic treatment for AD or other inflammatory diseases, common AD herbal medicine preparations or Chinese patent medicines; g. Within 4 weeks before the baseline received phototherapy (narrow-band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), sunbed or any other light-emitting device treatment; h. Within 6 months before the baseline received allergen-specific immunotherapy; i. Within 2 weeks before the baseline or within 5 half-lives of the drug (whichever is longer), systemically used (or expected to be needed throughout the study period) strong or moderate inhibitors or inducers of cytochrome P450 (CYP) (see Appendix II); j. Within 2 weeks before the baseline or within 5 half-lives of the drug (whichever is longer), systemically used (or expected to be needed throughout the study period) P-glycoprotein (P-gp) inhibitors (see Appendix II); k. Had received lymphocyte depletion therapy before (such as: alegrucilunab, anti-CD4 drugs, cladribine, rituximab, omalizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, darzalex); l. Within 3 months before the baseline or within 5 half-lives of the drug (if known, whichever is longer), received any treatment in clinical studies of drugs or medical devices, or was currently enrolled in another interventional study.
11. Those with any of the following medical histories:
a. Symptoms of bradycardia or related medical history; b. Second or third degree atrioventricular block; c. Cardiac arrest duration > 3 seconds; d. History of sick sinus syndrome or neurocardiac syncope. 12. Those with a history of uncontrolled diabetes (defined as > 9%). 13. Those with any systemic disease that may affect the evaluation of the trial results or active other skin diseases (such as psoriasis, lupus erythematosus, Netherton syndrome, chronic actinic dermatitis, dermatitis herpetiformis), or those with scars, freckles, tattoos, obvious pigmentation and other factors that may affect the evaluation of skin lesions at the affected sites.
14. Those with >= 2 grade peripheral neuropathy according to V5.0 during screening, and those with any significant neurological dysfunction remaining.
15. Those with a history of current active primary or secondary immunodeficiency diseases.
16. Those with previous disseminated herpes zoster or herpes simplex. 17. Those with a history of significant pulmonary diseases such as , pulmonary fibrosis, severe or poorly controlled asthma (except for mild intermittent asthma that does not require routine maintenance treatment).
18. Select patients who need intravenous antibiotics for hospitalization within the past 30 days or who need oral antibiotic treatment for active bacterial, fungal, viral, mycobacterial infections or other infections within the past 14 days before screening.
19. Select patients who have received any live or attenuated vaccines within the past 30 days before screening or who plan to receive any live or attenuated vaccines during the study period or within 30 days after the last administration.
20. Select patients who have a history of active tuberculosis within the past 1 year before screening or who have a positive tuberculosis test result within the past 1 month before screening. These are defined as:
a. Have a history of active tuberculosis infection and no evidence of clinical cure; b. Have imaging evidence (such as chest CT) indicating active tuberculosis in the subject at the time of screening; c. Have suspicious tuberculosis symptoms that cannot be excluded by the investigator's assessment (such as low fever, cough, night sweats, weight loss, etc.); d. Latent tuberculosis infection (LTBI): Have a positive tuberculosis test result during the screening period, but no clinical symptoms or signs of active tuberculosis; Detection methods include but are not limited to T-spot test, QuantiFERON-TB Gold test, PPD test. If the subject has started LTBI preventive treatment according to the guideline-approved protocol before randomization and has been treated for at least 1 month, the subject is eligible. To continue the study, the subject must agree to complete the recommended treatment course for LTBI; e. The result of the tuberculosis test: If the result of the first test is uncertain, a second test should be conducted. If the retest result is still uncertain, the subject should be excluded from this study. If the retest is positive, the subject should receive LTBI treatment. If the retest is negative and does not meet other tuberculosis exclusion criteria, the subject is eligible.
21. During the screening visit, abnormal results of blood routine tests were screened (repeated tests could be conducted for verification, and the decision was made independently by the researchers). The abnormalities included, but were not limited to:
a. White blood cell count \< 3.5 × 10\^9/L; b. \< 1.5 × 10\^9/L; c. Lymphocyte count \< 0.8 × 10\^9/L; d. count \< 100 × 10\^9/L; e. \< 9.0 g/dL. 22. During the screening visit, abnormal results of blood biochemistry (repeated tests are allowed for verification, and the determination is made independently by the researchers), including but not limited to:
a. Estimated \< 60 mL/min/1.73 m2; b. Estimated rate \< 60 mL/min; c. Creatinine level > 1.4 mg/dL or 123 μmol/L (for female participants); d. Creatinine level > 1.6 mg/dL or 141 μmol/L (for male participants). 24. Exclude participants who have a history of alcohol abuse within the past 1 year (with weekly alcohol intake exceeding 21 units for men and 14 units per week for women (1 unit = 360 mL of beer; or 150 mL of wine; or 45 mL of liquor)) or a history of drug abuse.
25. Accept those who have received any of the following treatments:
Within 12 weeks before the first administration of the drug:
Within 1 week before the first administration of the investigational drug.
1) Use antiplatelet drugs. Note: Based on the investigator's judgment, low-dose aspirin (dose \<= 100 mg, QD) for the purpose of preventing cardiovascular diseases is allowed; 26. Within 12 weeks before screening, those who have lost blood >= 400 mL (including trauma, blood collection, blood donation), or those who plan to donate blood during the study or within 1 month after the study.
27. Due to other reasons, unable to complete this study or considered unsuitable by the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: The high-dose group of ZL-82 tablets
Drug: The low-dose group of ZL-82 tablets
Drug: The placebo group
Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.
Participants will take the investigational drug orally for 16 weeks, 100mg each time, once a day.
The participants will take the investigational drug orally for 16 weeks, 2 tablets each time , once a day.
Compare the percentage changes in Eczema Area And Severity Index (EASI) scores from baseline between the ZL-82 tablets dose group and the placebo group.
Time frame: At the 16th week
Compare respectively the percentage changes of EASI scores from baseline in the ZL-82 tablets dose group and the placebo group
Time frame: At the 2nd, 4th, 8th and 12th weeks
Compare respectively the proportions of participants in the ZL-82 tablets dose group and the placebo group whose EASI scores have improved by at least 50% (EASI-50), 75% (EASI-75) and 90% (EASI-90).
Time frame: At the 2nd, 4th, 8th and 12th weeks
Compare respectively the proportions of participants in the ZL-82 tablets dose group and the placebo group who had an IGA score of 0 or 1 and showed a 2-point improvement compared to the baseline in the Investigator's Global Assessment (IGA) method.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
Compare the proportions of participants whose IGA scores improved by ≥ 2 points relative to the baseline in the ZL-82 tablet dose group and the placebo group respectively.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
The weekly average peak pruritus numerical rating scale (PPNRS) scores of the ZL-82 tablets dose group and the placebo group were compared respectively to evaluate the changes from baseline.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
Compare respectively the proportions of participants whose weekly average PPNRS scores relative to the baseline were ≥ 4 points in the ZL-82 tablets dose group and the placebo group.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
Compare respectively the changes in the body surface area (BSA) affected by AD relative to the baseline in the ZL-82 tablets dose group and the placebo group.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
The changes in Dermatology Life Quality Index (DLQI) relative to the baseline were compared respectively between the ZL-82 tablets dose group and the placebo group.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
The changes in the scores of the Patient-Oriented Eczema Measure (POEM) scale, a self-assessment scale for eczema, of the participants in the ZL-82 tablets dose group and the placebo group relative to the baseline were compared respectively.
Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks
health checkup
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.
vital signs
body temperature
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.
laboratory tests results
White blood cell
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
urobilinogen
Time frame: Screening period,Day141.If necessary, planned external visits to the participants must be conducted.
PR interval
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
ZL-82 tablets blood drug concentration-time curve
Time frame: Day1 Within 30 minutes before administration and 5minutes,15 minutes ,0.5 hours,1 hours,1.5 hours,2 hours,3 hours,4 hours,6 hours,8 hours after administration, Day15,Day29,Day57,Day85,Day113.
PK parameters of ZL-82 tablets in blood(Cmax )
Time frame: Day1 Within 30 minutes before administration and 5minutes,15 minutes ,0.5 hours,1 hours,1.5 hours,2 hours,3 hours,4 hours,6 hours,8 hours after administration
The steady-state plasma concentration (Cmin, ss) of ZL-82 tablets before administration (Pre-dose)
Time frame: Day1,Day15,Day29,Day57,Day85,Day113,If necessary, planned external visits to the participants must be conducted.
vital signs
blood pressure
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.
vital signs
respiration
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.
vital signs
pulse
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.
laboratory tests results
Red blood cell
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
platelet count
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
Neutrophil granulocyte
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
Total Protein
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
Albumin
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
total bilirubin
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
direct bilirubin
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
indirect bilirubin
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
globulin
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
alkaline phosphatase
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
total cholesterol
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
triglycerides
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
high-density lipoprotein
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
Low Density Lipoprotein
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
fasting blood-glucose
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
creatinine
Time frame: Day-28 to Day-1,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
urea nitrogen
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
Uric Acid
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
coagulation function
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
laboratory tests results
urine test
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
QRS interval
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
QT/QTc interval
Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.
PK parameters of ZL-82 tablets in blood(Tmax)
Time frame: Day1 Within 30 minutes before administration and 5minutes,15 minutes ,0.5 hours,1 hours,1.5 hours,2 hours,3 hours,4 hours,6 hours,8 hours after administration
adverse event
Adverse events, serious adverse events, suspected and unexpected serious adverse reactions (SUSAR), priority adverse reactions, incidence of adverse reactions
Time frame: From date of randomization until the date of completion of data collection, assessed up to 20 weeks
Eosinophil count
Evaluate the changes in PD biomarkers of ZL-82 tablets in participants with moderate to severe AD.
Time frame: Day1,Day15,Day29,Day57,Day85,Day113,If necessary, planned external visits to the participants must be conducted.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 22 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu Zenitar Biomedical Technology Co., Ltd →